Navigation Links
Patients with bowel disease eager to test 'fecal' therapy
Date:6/2/2011

matter from a healthy donor and injecting it into the patient's colon.

In 2003, a team led by Australian physician Thomas Borody published a report on successful treatment of six patients with longstanding ulcerative colitis with this approach. "Complete reversal of UC was achieved in all 6 patients following the infusion of human fecal flora," the authors reported. "These 6 cases document for the first time the total disappearance of chronic UC without the need for maintenance treatment."

"This is a fascinating idea, and the early studies show great promise, but we found that no one had looked at the social issues surrounding fecal transplantation," said Rubin. "Before we offer this, we wanted to find out how patients understood the process and take a look at the ethical issues that could also be raised by this therapy."

Like an organ transplant, fecal microbiota transplantation begins with finding a donor, often a family member. The treatment team collects a fresh stool sample, at least 200 to 300 grams. The sample is mixed with salt water in a blender and filtered to remove particulate matter. It can be administered to the recipient through a colonoscope, as an enema, orwhen the inflamed region is higher in the colonthrough a naso-gastric tube.

Rubin and colleagues Stacy Kahn, MD, and Rita Gorawara-Bhat, PhD, organized six focus groups in 2009-2010 with patients or parents of children with ulcerative colitis to "explore the attitudes and concerns" raised by this approach. They published their findings in the June issue of the journal Inflammatory Bowel Disease.

They found that 21 out of 22 patients or parents of patients were interested in trying FMT for themselves or their child; most wished it were already available. They viewed the treatment as more 'natural' than using drugs to control the disease, and easier and safer than currently available therapies. Many compared it to probiotics, a popular alternative
'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. A drug combination extends survival in refractory lung cancer patients
2. The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients
3. Arthritis patients taking newer treatments do not have an overall increased cancer risk
4. Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack
5. Study shows the HPV vaccine Gardasil doesnt increase disease activity in SLE patients
6. Inability to cry in patients with Sjogrens syndrome affect emotional and mental well-being
7. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
8. Heart Failure: Targeting the right patients for CRT-D
9. Zebrafish models identify high-risk genetic features in leukemia patients
10. Following trail of cell death in epilepsy patients to find ways to preserve brain health
11. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Cell Through In Vivo ... Imaging-, ... ) today introduced Bioware(R) Ultra cell lines,a range of ultra bright light ... cell lines are,10 to 100 times brighter than cell lines created using ...
... Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) announced that ... Nemours Center for Childhood Cancer Research entitled,"Radiation in ... at the American Association for Cancer Research (AACR),Annual ... Diego, California from,April 12-16, 2008., "The combination ...
... Sign Manufacturing and Distribution Agreement, GURGAON, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned subsidiary ... it has reached several,agreements with AstraZeneca. Two ... third agreement pertains to Omeprazole 40mg,tablets, and ...
Cached Biology Technology:Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: